Bicycle Therapeutics Plc (BCYC)
4.31
+0.21
(+5.12%)
USD |
NASDAQ |
Sep 02, 16:00
4.31
0.00 (0.00%)
After-Hours: 20:00
Bicycle Therapeutics Research and Development Expense (Annual) : 275.85M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 275.85M |
| December 31, 2024 | 216.26M |
| December 31, 2023 | 182.66M |
| December 31, 2022 | 103.86M |
| December 31, 2021 | 47.87M |
| Date | Value |
|---|---|
| December 31, 2020 | 34.11M |
| December 31, 2019 | 25.65M |
| December 31, 2018 | 20.73M |
| December 31, 2017 | 11.99M |
| December 31, 2016 | 9.771M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Autolus Therapeutics Plc | 128.59M |
| Akari Therapeutics Plc | 2.822M |
| Biodexa Pharmaceuticals Plc | 5.026M |
| DBV Technologies SA | 107.12M |
| Cellectis SA | 75.08M |